John Kovach, president and CEO of Lixte, said: “Lixte previously reported that lead compounds from each of two different classes of pharmacologic agents have significant inhibitory activity against
Ron Creeley, vice president of marketing and sales for Simulations Plus, said: “We’re very pleased that the FDA’s cardiovascular and renal products division has licensed our ADMET Predictor
The priority review is granted to applications in which a new indication or new drug product, if approved, has the potential to present a safe and effective therapy
Under the terms of the agreement, Archemix will receive an upfront payment of $6 million. Ribomic has the option, upon payment of a further fee, to convert the
The granted claims of the patent include an invention directed towards producing constructs for RNA interference (RNAi) techniques. The invention provides a ribonucleic acid (RNA) for use as
The Phase II study will enroll 80 patients with advanced head and neck, and non-small cell lung cancer at the National Center for Rehabilitative Auditory Research at the
This new trial is intended to evaluate the safety and immunogenicity of an improved formulation of the vaccine containing an adjuvant that is expected to result in long
Under terms of the agreement, Sonus was granted exclusive rights to develop two core compounds for all prophylactic and therapeutic uses in humans. Additionally, Sonus was granted rights
In a 173-patient, placebo and active comparator-controlled double blind Phase III study with a seven-week open label follow on, IPX056 was shown to be effective versus placebo in
The company is producing up to 40 million doses of Fluvirin, with the World Health Organization recommended change in all three virus strains included in the influenza vaccine
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.